

IL10 is Immuno-suppressive
on Myeloid Cells (PRIMING PHASE)




FIG. 1A

IL10 is Immuno-stimulatory on T Cells
(EFFECTOR PHASE)




FIG. 1B




FIG. 2A







FIG. 2B








FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 4G




FIG. 4H




FIG. 4I




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 5F




FIG. 5G




FIG. 5H





FIG. 5I






FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E




FIG. 7F




FIG. 8A




FIG. 8B

Colon 26 Colon Carcinoma (100% ORR/TGI)




FIG. 8C

A20 Lymphoma (100% ORR/TGI)




FIG. 8D




FIG. 8E-1




FIG. 8E-2




FIG. 8E-3




FIG. 8F




FIG. 8G




FIG. 8H




FIG. 8I




FIG. 9A




FIG. 9C





FIG. 9B






FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E





FIG. 11A-1






FIG. 11C




FIG. 11B




FIG. 11E




FIG. 11D




FIG. 11F




FIG. 11G




FIG. 11H






FIG. 11I






FIG. 12D




FIG. 12E




FIG. 12F




FIG. 12G




FIG. 13A




FIG. 13B





FIG. 13C



Group	n
Control (mIgG1)	7
PD-1 antagonist Ab, 10mg/kg	7
IL10M11, 0.2mg/kg	7

FIG. 14A




FIG. 14B





FIG. 14C



Group	n
Control (mIgG1)	8
PD-1 antagonist Ab, 10mg/kg	8
IL10M11, 0.2mg/kg	8

FIG. 15A




FIG. 15B




FIG. 15C

Group	n
Control (mIgG1)	8
PD-1 antagonist Ab, 10mg/kg	8
IL10M11, 0.2mg/kg	8
Combination (PD-1 antagonist Ab (10mg/kg) + IL10M11 (0.2 mg/kg)	8




FIG. 16A




FIG. 16B




FIG. 16C

mIL-10 HDD Treated MC38 @ Day 28




FIG. 17A-1




FIG. 17A-2

mIL-10-mIgG1 Treated 4T1 @ Day 33




FIG. 17B-1




FIG. 17B-2




FIG. 18A




FIG. 18B




FIG. 19A





FIG. 19B






FIG. 19C




FIG. 20A




FIG. 20B




FIG. 21B






FIG. 21A



Group	n
Control (mlgG1)	8
PD-1 antagonist Ab, 5mg/kg	8
IL10M11, 0.2mg/kg	8
Combination (PD-1 antagonist Ab (5mg/kg) + IL10M11 (0.2 mg/kg)	8
Ctrl-IL10	8
mPD1-mIL10	8

22A



FLG²³